Meeting
2017 ASCO Quality Care Symposium
Improving hepatitis B screening prior to rituximab at a multispecialty urban hospital.
Authors
Lakshminarayanan Nandagopal
University of Alabama at Birmingham, Birmingham, AL
Lakshminarayanan Nandagopal, Ravi Kumar Paluri, Barbara Gleaton, Diego Alonso De Idiaquez, Lisle Nabell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Patient Safety and Science of Quality
Track
Patient Safety,Science of Quality
Sub Track
Quality Improvement
Citation
J Clin Oncol 35, 2017 (suppl 8S; abstract 176)
DOI
10.1200/JCO.2017.35.8_suppl.176
Abstract #
176
Poster Bd #
C5
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or ofatumumab.
First Author: Paola Ghione
Poster
2016 ASCO Annual Meeting
Patterns of hepatitis B reactivation and liver test abnormalities in patients with chronic lymphocytic leukemia (CLL) treated with idelalisib plus an anti-CD20 antibody.
First Author: Andrew David Zelenetz
Poster
2023 ASCO Quality Care Symposium
Hepatitis B serology testing in patients with cancer initiating anticancer therapy.
First Author: Julie Braish
Poster
2022 ASCO Quality Care Symposium
Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative.
First Author: Sarah J. Mah